Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 15 June 2024

Created: 15 June 2024

Last Updated: 15 June 2024

NEW YORK, June 15, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq: BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/biogen-inc-investigation.

Posted: 2024-06-15 10:04:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: BIOGEN STOCK NOTICE: Lose Money on your Biogen Inc. (Nasdaq: BIIB) Investment? BFA Law Encourages You to Contact the Firm before July 22, 2024 Court Deadline - Newscast

Ticker: Biogen Alzheimer’s drug gets second look in EU; Ford takes $165M hit on slow recall

Thu, 14 Nov 2024 17:08:00 GMT A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Thu, 14 Nov 2024 10:52:00 GMT Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an ...

Biogen Inc. stock underperforms Wednesday when compared to competitors

Wed, 13 Nov 2024 14:06:00 GMT Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.02% to 5,985.38 and ...

5 Reasons Biogen’s Shares Have Dropped 36% in 2024

Wed, 13 Nov 2024 06:55:00 GMT A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen's shares down this year.

Here's Why Biogen Inc. (BIIB) is a Strong Value Stock

Tue, 12 Nov 2024 06:40:11 GMT For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...